Group 1 - The arbitration court ruled that Regen Biotech, Inc. is prohibited from selling AestheFill in China and must acknowledge that 达透医疗 is the exclusive distributor of the product in the region [1][2] - 达透医疗 has filed for arbitration due to Regen's breach of contract, seeking to confirm the validity of the exclusive agency agreement and claiming initial damages of RMB 1.6 billion, with the right to adjust this amount based on case developments [1] - The arbitration court's decision mandates that Regen must continue supplying AestheFill to 达透医疗 until the final arbitration ruling is made [1] Group 2 - *ST苏吴 stated that the company is currently unable to continue selling AestheFill, and the actual impact will depend on whether Regen complies with the arbitration court's decision [2] - The arbitration court will continue to form an arbitration panel to further review the case, indicating that the final outcome remains uncertain [2]

Core Viewpoint - The dispute over the exclusive agency rights for the "AestheFill" product has intensified between *ST Suwu and Aimeike, following arbitration initiated by *ST Suwu's subsidiary, Datou Medical [1][2]. Group 1: Arbitration Developments - Datou Medical's request for temporary measures was approved, resulting in a temporary ban on the sale of AestheFill products by Regen in mainland China [1][3]. - The arbitration case was accepted by the Shenzhen International Arbitration Court on August 7, 2025, with Datou Medical seeking to confirm the validity of the exclusive agency agreement and claiming initial damages of 1.6 billion RMB [2]. - The arbitration decision prohibits Regen from selling AestheFill products in mainland China until the arbitration ruling is made and mandates that Regen must continue supplying the product to Datou Medical [3]. Group 2: Company Performance Impact - Both Aimeike and *ST Suwu are experiencing financial pressure, with Aimeike's revenue declining by 21.59% to 1.299 billion RMB and net profit down 29.57% to 789 million RMB in the first half of the year [4]. - *ST Suwu reported a revenue drop of 27.08% to 636 million RMB, with a net loss of 44.42 million RMB, marking a significant decline of 281.63% [4].

Core Viewpoint - Jiangsu Wuzhong is facing a significant setback due to the unilateral termination of its exclusive agency rights for the AestheFill product by Regen Biotech, which the company claims is an act of "malicious breach of contract" by its partner Aimeike [2][8]. Group 1: Agency Dispute - Jiangsu Wuzhong's subsidiary, Datuo Medical, received a termination notice from Regen Biotech regarding the exclusive distribution agreement for AestheFill [2][4]. - Regen Biotech alleges that Datuo Medical violated the agreement by transferring the agency rights to its parent company, Jiangsu Wuzhong Meisheng Biotechnology [4]. - The termination has led to Regen Biotech refunding payments for undelivered orders, further complicating Jiangsu Wuzhong's financial situation [2]. Group 2: Financial Impact - AestheFill, known as the "童颜针" (youthful needle), was a key product for Jiangsu Wuzhong, contributing significantly to its revenue and profit [13]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion, with AestheFill sales accounting for 326 million, representing 20.42% of total revenue [13]. - The loss of exclusive agency rights could drastically reduce Jiangsu Wuzhong's income and profit, as AestheFill was a major driver of its financial recovery [13]. Group 3: Company Performance and Challenges - Jiangsu Wuzhong has struggled with poor financial performance, reporting losses in multiple years since 2018 [11]. - The company is also facing potential delisting due to significant financial irregularities, including inflated revenues and profits from 2020 to 2023 [14]. - The stock price of Jiangsu Wuzhong has declined by 4.71%, closing at 1.62 yuan, reflecting investor concerns over its financial stability [14].

Core Viewpoint - A dispute has arisen between two A-share companies regarding the exclusive distribution rights of the AestheFill product, with *ST Suwu asserting its rights against Regen Biotech, a subsidiary of Aimeike [2][3] Group 1: Dispute Details - *ST Suwu claims that Regen Biotech intends to terminate the exclusive distribution agreement for AestheFill in mainland China, citing alleged violations of the agreement by *ST Suwu and its executives [2][3] - Regen Biotech has sent a termination notice to *ST Suwu, asserting that the latter has transferred the distribution rights to its controlling shareholder, Wu Zhong Meixue, which they claim violates the agreement [2][3] - *ST Suwu refutes these claims, stating that there has been no transfer of rights and that the exclusive distribution agreement remains legally binding until 2032 [3] Group 2: Product and Market Impact - AestheFill is a regenerative injection product developed by Regen Biotech, primarily composed of PDLLA microspheres and sodium carboxymethyl cellulose, aimed at skin rejuvenation [4] - The product was first approved for sale in South Korea in 2014, and *ST Suwu acquired a 51% stake in the distributor, Dato Medical, in 2021 for 166 million yuan [4][5] - AestheFill generated significant revenue for *ST Suwu, contributing 3.26 billion yuan to the company's total revenue in 2024, accounting for 20.42% of total revenue and 34.80% of gross profit [6] Group 3: Corporate Developments - Aimeike recently acquired 85% of Regen Biotech for approximately 1.386 billion yuan, gaining control over the company and integrating it into its financial statements [5][6] - The sales performance of AestheFill is critical for *ST Suwu, especially as the company faces a potential delisting due to regulatory issues related to financial misreporting [6]